Qiagen (QGEN) said Thursday it intends to open a new facility in Esplugues de Llobregat in Spain in early 2026 and will move its QIAstat-Dx operations within the Barcelona area to the new site.
The new 8,000-square-meter facility will cover the entire value chain for the QIAstat-Dx system for syndromic testing to trace the cause of an illness in respiratory, gastrointestinal and meningitis/encephalitis, the company said.
Qiagen said the new facility will house its research & development, production, sales, marketing, quality assurance, and regulatory affairs teams.
The new site will also serve as a center of excellence for R&D in microfluidics, as well as system and assay development, the company said.
Price: 43.55, Change: -0.20, Percent Change: -0.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。